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Aims Besides the inhibition of the sodium inward current, vernakalant also inhibits the ultra rapid rectifier (IKur) and transient
outward current (Ito). Inhibition of these currents increases contractility in canine atrial myocytes and goat atria. We
investigated the effect of vernakalant on early repolarization and contractility in normal and electrically remodelled atria.
...................................................................................................................................................................................................
Methods
and results
Goats were implanted a pressure catheter, piezoelectric crystals, and electrodes to obtain atrial contractility and
effective refractory period (ERP). The active component in pressure distance loops was used to compute the atrial
work index (AWI). Experiments were performed in normal and electrically remodelled atria at clinically relevant
plasma levels of vernakalant. As a positive control, the Ito/IKur blocker AVE0118 was investigated. Monophasic
action potentials were recorded in anaesthetized goats and in explanted hearts to determine changes in action po-
tential morphology. Vernakalant did not affect atrial work loops during sinus rhythm. Likewise vernakalant did not
increase atrial fractional shortening or AWI during pacing with fixed heart rate and AV-delay. In contrast, AVE0118
did increase AWI, with a positive force frequency relation. Both in normal and remodelled atria, vernakalant
strongly increased ERP but did not prolong early repolarization.
...................................................................................................................................................................................................
Conclusion In goat atria, vernakalant does not have an atrial positive inotropic effect and does not affect early repolarization.
At high rates vernakalant may even have a negative inotropic effect.
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Introduction
Patients with atrial fibrillation (AF) have reduced exercise tolerance
and a five-fold increase in stroke risk.1 Electrical or pharmacological
cardioversion of AF is often performed to improve symptoms caused
by rapid and irregular ventricular activations and restore the active
atrial contribution to ventricular filling. However, the atria need to re-
cover from low atrial contractility after termination of AF. This transi-
ent loss of contractility contributes to decreased exercise tolerance
and might lead to thromboembolic events after termination of AF.1
The recovery of atrial contractility is dependent on factors such as
underlying heart disease, atrial diameter, and the duration of AF.1 In the
goat model a close correlation between AF-induced electrical remod-
elling and loss of atrial contractility after several days of AF (dAF) has
been described in.2 Therefore, normalizing electrophysiological prop-
erties in the electrically remodelled heart could be a therapeutic target
to enhance atrial contractility and thereby increase exercise tolerance
and reduce stroke risk in the first days post-cardioversion.
In canine atrial myocytes changes in action potential morphology af-
fect atrial cellular contractility.3–5 Specifically, increased plateau ampli-
tude or prolongation of plateau duration facilitates Ca2þentry through
the reverse mode of the Naþ/Ca2þexchanger (NCX) and leads to
more pronounced cell shortening.3 In atrial myocytes the transient
outward current (Ito) and the ultra rapid rectifier (IKur) largely
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determine the early repolarization. Inhibition of these currents delays
early repolarization and causes a positive inotropic effect in human
atrial trabeculae and improved atrial contractility in the goat.6,7
Vernakalant has been available in European countries since 2010
for acute cardioversion of AF.8 Vernakalant inhibits both depolarizing
sodium current and repolarizing potassium currents including the
transient outward current (Ito) and the ultra rapid rectifier (IKur).
9
Moreover, Torp-Pederson et al.10 showed that a 90-day oral treat-
ment of vernakalant can be safely used in haemodynamically stable
AF patients. These properties of vernakalant might allow a positive
inotropic treatment strategy after cardioversion. The goal of this
study is to explore the possible atrial positive inotropic effect of
vernakalant.
Methods
Animal model
The research protocol was approved by the local ethics committee and
complied with the European directives concerning the use of animals for
scientific purposes. Ten goats with a body weight of 60 ± 5 kg were
included into this study. The goats were anaesthetized (i.v. sufentanyl
6mg/kg/h and midazolam 0.8 mg/kg/h) and the thorax was opened using a
left-sided approach. To determine local contractility, piezoelectric crys-
tals were placed on the right and left appendage (Figure 1A) and left ven-
tricular free wall for segment length recordings. Additionally, on both
atria and the left ventricle a bipolar electrode was fixated, ensuring that
the site of electrode implantation would not interfere with the free
movement of the segments. After a 2-week recovery period an additional
trans-venous 5 Fr Micro-Tip pressure catheter (Millar Inc., Houston,
Texas, USA) was chronically implanted in the right atrium. To prevent
thrombus formation, the goats were anti-coagulated with a daily dose of
nadroparin (2850 IU SC, GlaxoSmithKline, Zeist, The Netherlands).
Study protocol
Three days after pressure catheter implantation, atrial contractility and
electrophysiology (EP) were investigated in awake goats. The sequence
of experiments was consistent for each goat and followed the study
protocol presented in Figure 1B. The first experiment (control, CTL) was
performed before any episode of AF was induced. The second experi-
ment was performed after 2dAF. AF was initiated and maintained by atrial
burst pacing for as described previously in.11 Subsequently, after >_5 days
of recovery from AF, AF was reinitiated for another 2 days to perform a
positive control experiment with AVE0118. Finally, after full recovery AF
was reinduced again for 2 days for a final open chest experiment under
anaesthesia (i.v. sufentanyl 6 mg/kg/h and midazolam 0.8 mg/kg/h). Based
on the work of Garratt et al. no residual effect of the previous AF epi-
sodes on AF stability is expected on the atria.2,12
Drug administration protocols
We investigated two different stable plasma levels of vernakalant, about
3 and 5 mg/ml comparable to clinical relevant concentrations. The first
and lower dose (LD) was reached by a 15-min loading infusion at 0.25
mg/kg/min followed by a maintenance infusion of 0.13 mg/kg/min. The
higher dose (HD) was reached after 15 min loading at 0.30 mg/kg/min fol-
lowed by a maintenance dose of 0.22 mg/kg/min. All contractility and EP
measurements were performed 15 min after start of the maintenance in-
fusion for both dose levels.
The atrial positive inotropic compound AVE0118 was infused at a rate
of 1.0 mg/kg/h. Time between experiments allowed full washout (>5 half
lives) of both vernakalant and AVE0118.
Haemodynamic and electrophysiological
measurements
Measurements were performed at baseline (saline infusion, BL) and the
two different dosages of vernakalant (LD, HD) or in the presence
AVE0118. At each of these conditions the atrial effective refractory
period (ERP) was measured and contractility recorded during sinus
rhythm and during right atrial (RA) pacing at different basic cycle lengths
(BCLs). ERP was measured with a S1S2 protocol, using a pacing output at
four times above threshold.
Contractility recordings were performed during atrial and ventricular
pacing with a fixed delay from atrium to ventricle (150 ms), about 30 ms
shorter than the intrinsic AV-conduction. In previous goat studies11 we
have observed a shift in the Wenckebach cycle length after vernakalant
infusion. As the occurrence of AV block dramatically alters pre- and after-
load conditions of the atrium, we performed Segment lengths, RA pres-
sures (Pra) and electrograms were recorded for 20 s (eight-bit AD
conversion, 250 Hz sampling frequency, Sonometrics corporation,
London, Ontario, Canada) (Figure 1C).
During the final open chest experiment the effect of vernakalant on
the morphology of the atrial action potential duration (APD) was deter-
mined using a Franz catheter (7F-110 cm–2 mm, Sachs Elektronik,
Germany). Monophasic action potentials (MAPs) were recorded on the
epicardial RA wall at a 1kHz sampling frequency (Mpaq, Maastricht instru-
ments, The Netherlands).
Haemodynamic analysis
The atrial haemodynamic cycle consists of a passive and an active compo-
nent. The active contraction is delineated by atrial shortening and an atrial
pressure rise (Figure 1C). The active phase ends when the volume has re-
turned to its initial value (Figure 1D). This point is followed by ventricular
contraction, leading to passive pressure, and distance changes.
Haemodynamic parameters of the active contraction, such as diastolic
distension, fractional shortening (FS), and developed RA pressure (DP),
were manually determined offline in 20 s recordings (SonoSOFT 3.3.52,
Sonometrics corp, London, Ontario, Canada) as described previously in.2
In the same recordings the atrial work index (AWI) was derived from the
pressure-distance loops (Figure 1D). Custom-made analysis software
(MATLAB 8.1, The Mathworks, Inc., Natick, Massachusetts, USA) was
used to calculate AWI as the area under the curve in the active compo-
nent of the loop (Figure 1C). Only signals recorded during the resting
phase of the respiratory cycle were analysed.
Optical mapping
In seven goats (57 ± 9 kg) electrodes were implanted on the pericardium
at the site of the left atrium that allowed trans-pericardial stimulation.
Optical mapping was performed after 3 weeks of AF induction. Hearts
were excised under anaesthesia (sufentanyl 6 mg/kg/h and midazolam 0.8
What’s new?
• Vernakalant does not have an atrial positive inotropic effect in
normal or electrical remodelled atria during sinus rhythm.
• Vernakalant may have negative inotropic effects at high
frequencies.
• The lack of inhibition of initial repolarization prevents vernaka-
lant to increase atrial contractility.
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mg/kg/h, i.v.) and perfused with Krebs-Henseleit solution and prepared
for optical mapping as previously described in detail.13 In brief, the hearts
were loaded with the voltage sensitive dye di-4-ANEPPS. Fluorescence
movies of a 2  2 cm area at the site of the crista terminalis were re-
corded with a 100  100 pixel CCD camera (Micam Ultima, Brainvision
inc., Tokyo, Japan). The excitation-contraction uncoupler blebbistatin (10
mM) was used to prevent movement artifacts in the recorded optical po-
tentials. Optical action potentials were recorded at a cycle length of 300
ms pacing in the presence of 0, 10, and 30 mM of vernakalant.
Statistics
Data were analysed using IBM SPSS statistics version 19.0.0. Parameters
were tested with linear mixed effects model using a diagonal covariance
structure with drug, dose, pacing cycle length, and/or stage of remodelling
taken as fixed variables and animal identification taken as random variable.
Results are reported as estimated mean ± SEM. Statistical significance
was taken as P < 0.05.
Results
Haemodynamics effects of vernakalant
during sinus rhythm and pacing
2dAF strongly reduced RA contractility. During sinus rhythm the
AWI declined from 4.7 ± 1.8 at CTL to 1.1 ± 0.7 mmmmHg at 2dAF.
Infusion of vernakalant shifted the atrial work loop to the right in
A B
C D
Figure 1 Outline of the experimental protocol and signals acquired during the experiments. (A) Diagram of implanted sensors in and on the goat
atria for the measurements in awake goats. Abbreviations: SVC, superior caval vein; IVC, inferior caval vein; and PV, pulmonary vein. (B) Outline of
the study protocol depicts sequence of experiments. Within the first three studies atrial contractility (contrac) and EP were investigated in the awake
goat, at baseline and after vernakalant or AVE0118 infusion. Vernakalant was investigated in atria without any previous AF episode (control) or after
2dAF. AVE0118 was only investigated after 2dAF at a single dose. The effect of vernakalant on MAPs was recorded under anaesthesia. The intervals
between experiments were designed to be >5 half lives of the respective compound to ensure drug washout. Additionally the intervals allowed full
recovery from the previous AF episode before AF was reinduced. (C) Example traces of 1.5 s during RA pacing, in order from top to bottom: left ven-
tricular segment length, RA segment length, RA pressure, left atrial (LA) electrogram, and left ventricular electrogram. Note that the LA electrogram
is depicted because the RA electrodes are used for pacing. Dotted arrows indicate the start of atrial or ventricular contraction. The pacing artifact
was used to identify initiation of atrial activation. (D) The atrial work loop comprises the RA pressure and the distance of the segment. The AWI was
calculated as the surface of the loop during active contraction indicated by the grey area. The active part of the loop begins at the start of atrial con-
traction and ends when the distance returned to the length at the start of contraction.
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both control and 2dAF experiments (Figure 2). Despite this increase
in preload during sinus rhythm, vernakalant restored or increased
AWI neither in control nor in 2dAF experiments.
To rule out possible AV-delay dependent effects, we performed
pacing with fixed atrium to ventricle delay. Haemodynamic param-
eters, such as end-diastolic segment lengths, FS and DP are summar-
ized in Table 1. FS in CTL experiments was comparable between
both atria. Vernakalant did not significantly change FS and DP. In
correspondence with the AWI, FS decreased in both atria after
2dAF. Also under these conditions, vernakalant did not increase or
restore FS in either atrium. Left ventricular FS was not affected by
vernakalant (data not shown).
To explore possible rate dependent effects we also investigated
the AWI at 450, 350, and 250ms BCL in CTL and in 2dAF experi-
ments (Figure 3A). As during sinus rhythm, AWI was strongly reduced
in 2dAF experiments. Vernakalant did not significantly affect AWI at
Atrial work during sinus rhythm
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Figure 2 (A) Representative recordings of pressure distance loops during sinus rhythm in control and 2dAF experiments. Despite a rightward shift
apparent for both experiments, no increase in AWI can be appreciated. (B) All data AWI during sinus rhythm in control and 2dAF experiments.
Control experiments are depicted in green and 2dAF experiments are depicted in red. 2dAF significantly reduced AWI but vernakalant did not affect
AWI in either control or in 2dAF goats.
............................................................... .................................................................
....................................................................................................................................................................................................................
Table 1 Atrial haemodynamics
Control 2dAF
Baseline Low dose High dose Baseline Low dose High dose
Diastolic length (mm) Left atrium 27.9 ± 2.3 30.5 ± 2.3** 30.4 ± 2.3* 29.0 ± 2.3 30.8 ± 2.3* 30.8 ± 2.3*
Right atrium 19.1 ± 1.7 20.1 ± 1.7* 20.1 ± 1.7* 22.0 ± 1.5 23.2 ± 1.5* 23.0 ± 1.5*
FS Left atrium 0.21 ± 0.04 0.22 ± 0.04* 0.21 ± 0.03 0.16 ± 0.03 0.12 ± 0.02* 0.12 ± 0.02*
Right atrium 0.22 ± 0.02 0.17 ± 0.2* 0.23 ± 0.02 0.12 ± 0.03# 0.09 ± 0.03 0.10 ± 0.03
Developed Pressure (D mmHg) Right atrium 1.3 ± 0.4 1.2 ± 0.4 1.7 ± 0.4 0.87 ± 0.32 0.26 ± 0.32 0.47 ± 0.32
Effect of vernakalant on average atrial haemodynamic characteristics determined in 20 s recording. Cardiac rhythm was controlled by RA pacing at 450 ms with a fixed AV-delay
of 150 ms. Vernakalant vs. control.
*P < 0.05; **P < 0.01; 2dAF vs. control; #P < 0.05
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Figure 3 (A) AWI measured during pacing with a fixed AV-delay (150 ms) at three different cycle lengths (450, 350, and 250 ms BCL). No signifi-
cant effects occurred at 450 and 350 ms but a drop in AWI occurred at 250 ms cycle length pacing. (B) ERPs measured in the right atrium. At all cycle
lengths the ERP increased in the presence of vernakalant. Vernakalant vs. BL; **P < 0.01; ***P < 0.001. HD vs. BL; #P < 0.05,
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450 and 350 ms, but at the shortest cycle length, AWI significantly
decreased at the highest dose. Revealing a use-dependent effect on
the atrial contractility.
Monophasic APD and excitability
We hypothesized that delaying ‘early’ repolarization will lead to an in-
crease in both ERP and AWI. As described earlier, no positive ino-
tropic effect of vernakalant was found in the awake goats in different
conditions. Yet, vernakalant strongly increased ERP in a dose-
dependent manner. The degree of increase was comparable in both
CTL and 2dAF experiments as can be appreciated in Figure 3B.
Therefore, the lack of positive inotropic effect could not be explained
by an inadequate dose that did not affect atrial electrophysiological
properties.
To further explore the effects of vernakalant on early repolariza-
tion, we performed ERP and MAP measurements in a small subset
(n = 6) in the above described goats. These experiments were per-
formed after 2dAF. APD30, APD75, and the plateau potential were
not affected by vernakalant while ERP was significantly increased
(Figure 4). The prolongation of ERP without APD prolongation
implies a reduction in excitability. This class I action should affect elec-
trophysiological parameters describing excitability. Therefore we
also explored the effect on pacing threshold and interatrial
conduction time. Pacing thresholds were increased from 0.95 ± 0.12
mA at baseline to 1.09 ± 0.17 mA and 1.21 ± 0.19 mA (P = 0.041),
LD and HD respectively. Furthermore the interatrial conduction
time prolonged from 73 ± 7ms at baseline to 97 ± 17 and 105± ms (P
< 0.001), LD and HD, respectively.
We also evaluated action potential morphologies with high-
resolution optical mapping (n = 7) of the RA wall. In agreement with
the earlier findings, vernakalant did not change the action potential
morphology (Figure 5). Only a minor prolongation (þ4.3 ± 5.7 ms) of
APD20 was observed at a concentration of 30 mM.
Positive inotropic effect of AVE0118
In six awake goats, we also investigated AVE0118 after 2dAF. Dosage
was chosen based on historical data to achieve comparable ERP pro-
longations to vernakalant. Figure 6 shows that both drugs produced
comparable and significant prolongations of ERP. AVE0118 displayed
a moderate frequency-dependent increase in AWI. At a BCL of
450ms AVE0118 did not increase AWI but it did increase AWI from
4.6 ± 1.9 to 6.6 ± 4.4 mmmmHg and from 8.7 ± 4.4 to 13.5 ± 6
mmmmHg at pacing intervals of 350 and 250 ms, respectively. In
contrast, vernakalant exhibited a negative frequency-dependent rela-
tionship that became significant at 250 ms BCL.
Epicardial monophasic action potential
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Figure 4 (A) MAPs recorded (BCL of 350 ms) on the RA epicardial wall in the anaesthetized goat. MAPs were normalized to the maximal ampli-
tude. Prior to the experiments AF was maintained for 2 days to induce electrical remodelling. (B) ERP in the right atrium at 350 ms BCL. (C) Average
level of the action potential from 10 to 50 ms after the upstroke and the duration to 30 and 75% recovery of the action potential. All measurements
were performed at 350 ms BCL. Vernakalant vs. BL; **P < 0.01; ***P < 0.001.
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A B
C
Figure 5 Atrial action potentials recordings after 3 weeks of AF using optical mapping. Isolated atria were perfused with Krebs-Henseleit solution
only and with two concentrations of vernakalant. (A) Illustration of the isolated goat atria with the recorded location indicated on the right atria by a
black rectangle. (B) The three panels show isochronal maps with different concentrations of vernakalant during pacing at 300 ms BCL. The lower
panel illustrates three representative normalized (to maximal amplitude) and superimposed optical action potentials, illustrating a lack of effect on
APD and morphology. (C) Effect of vernakalant on the APD at ADP20, APD30 and APD80 in the seven individual atrial preparations. Vernakalant vs.
baseline; * P < 0.05
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Figure 6 Left. Effect of vernakalant and AVE0118 on atrial refractory period in awake goats. The effect was measured at three different cycle
lengths. Dosage of AVE0118 was targeted to result in a comparable increase of ERP. Right. The effect of vernakalant and AVE0118 on AWI. AVE0118
showed a moderate increase in AWI with de largest effect at 250 ms. In contrast, vernakalant did not increase AWI and revealed a negative force fre-
quency relation.
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Discussion
This study investigates the effect of vernakalant on atrial contractility
in normal and electrically remodelled atria. We hypothesized that
the IKur inhibiting properties of vernakalant would cause an increase
in calcium influx by slowing early repolarization and would therefore
increase atrial contractility. However, vernakalant did not increase
atrial contractility or the work index and at shorter cycle lengths
even reduced atrial contractility. These effects of vernakalant were
found in both normal and electrically remodelled atria despite signifi-
cant prolongation in atrial refractoriness. In addition, vernakalant did
not affect early repolarization of the action potential, in keeping with
its lack of effect on atrial contractility.
Restoration of atrial contractility after
cardioversion of AF
Reduced atrial contractility is commonly observed after spontaneous,
electrical and pharmacological cardioversion of AF.1 This reduction
in atrial contractility is associated with decreased left ventricular func-
tion and reduced exercise tolerances.1,14 After cardioversion, im-
provement of left ventricular function and oxygen extraction may
take up to 1 month after cardioversion, illustrating a delayed im-
provement of exercise tolerance.15 Therefore, acutely restoring atrial
contractility might be an attractive strategy to improve recovery
from AF. However, many positive inotropic strategies (e.g. b-adren-
ergic stimulation and phosphodiesterase-III inhibitors) have proar-
rhythmic effects on the ventricles.16
In the goat model of AF, we have previously demonstrated that
the initial decrease in atrial contractility went along with atrial elec-
trical remodelling.2 Electrical remodelling is characterized by shorten-
ing of the APD due to downregulation of ICa,L and the upregulation of
the inward rectifying current IK1.
17 The ICa,L is—besides release of Ca
from the sarcoplasmatic reticulum—the most important source of
intracellular free Ca2þand an important determinant of atrial con-
traction. Indeed, Wakili et al.4 demonstrated that atrial tachypacing
induced action potential shortening and was associated with a reduc-
tion in peak ICaL, reduced Ca
2þ transients and an attenuation of cell
shortening. Interestingly they demonstrated that in these cells a res-
toration of control-like action potentials, by action potential clamp
experiments, increased Ca2þ transients and improved cell shortening.
Furthermore pharmacological changes in action potential, by modu-
lating acetylcholine-mediated potassium current, reveals a strong re-
lation between APD and contractility.5 These observations are in
agreement with our previous work where we demonstrated that ac-
tion potential morphology in non-remodelled atrial myocytes, more
specifically the plateau phase, is crucial for cellular contractility.3,18
Elevation of the action potential plateau in atrial myocytes by blocking
the atrial specific IKur current in combination with the transient out-
ward current (Ito) by AVE0118 revealed a linear relationship between
plateau duration and cell shortening.3 de Haan et al.6 translated this
observation to a whole animal model, demonstrating that AVE0118
prolonged plateau duration and fully restored atrial work in re-
modelled goat atria. Given that vernakalant is a known Ito and Ikur
blocker in HEK cell expression systems9, a positive inotropic effect
could be expected for vernakalant. However, despite a marked in-
crease of ERP, we did not detect any effect on AWI or FS during sinus
rhythm. In fact, pacing at higher frequencies revealed a negative ino-
tropic effect.
Why does vernakalant not increase atrial
contractility?
Loss of atrial contractility and disappearance of action potential plat-
eau after cardioversion of AF is caused by attenuated calcium transi-
ents and reduced cytosolic [Ca2þ]. Specifically, the down-regulation
of L-type calcium channels and up-regulation of repolarizing Kþ-cur-
rents are responsible for the loss of contractility and action potential
plateau.17 Hence, increasing calcium influx through L-type calcium
channels, by e.g. beta adrenergic stimulation or an L-type channel
agonist, will only have a limited effect in electrically remodelled atria.
Indeed, in the goat model of AF the sympathomimetic drug dobut-
amine or the L-type Ca2þ agonist BayY5959 had no or a limited ef-
fect on atrial work.6 Alternatively, calcium entry that occurs in the
early phase of repolarization through the reverse mode of the NCX
may offer a potential target. Indeed, patch clamp experiments have
provided evidence that the positive inotropic effect of AVE0118 is
mediated by Ca2þentry through this reverse mode of the NCX dur-
ing early repolarization.3 Based on the data found in the HEK cells
one might expect a similar effect in of vernakalant on early repolariza-
tion.9 However, in this series of experiments, vernakalant only led to
a small increase in APD20 as measured in the optical action potentials
with a negligible effect size of only 4 ms. Moreover, vernakalant did
not alter the APD30 or the plateau phase. This absence of an effect
on the action potential plateau may in part explain why vernakalant
did not possess any positive inotropic effect. Of note, Wettwer
et al.19 observed a similar lack of effect on the plateau phase in iso-
lated human trabeculae. Despite a small but significant prolongation
of the APD20 in trabeculae of chronic AF patients, vernakalant did
not increase the membrane potential during the plateau phase.
Various processes could have prevented an elevation of action po-
tential plateau and an increase of contractility. It might be that the
dosage used was not sufficient to substantially inhibit IKur. In the op-
tical mapping experiments we saw a small APD20 increase at a high
concentration of vernakalant. This minor prolongation of APD20 was
found at a concentration that is about three-fold higher than the
therapeutic plasma concentration. Such a condition was not investi-
gated in vivo because we aimed to explore vernakalant’s positive ino-
tropic potential at clinically relevant plasma concentrations. Further,
the degree of remodelling may have affected Ca2þhandling to such
an extent that a positive inotropic effect through the NCX pathway
could no longer be possible. However, in this case a positive ino-
tropic effect would have occurred in healthy atria, which was not the
case in our experiments. Moreover, in the same animals AVE0118
did increase atrial contractility at similar baseline conditions. Taken
together, these findings indicate that the IKur inhibition that has been
shown by others9 has a limited effect on early repolarization and thus
does not increase atrial contractility.
Class I effects of vernakalant
In a previous study, we have reported that vernakalant’s main antiar-
rhythmic effects in the awake goat are a slowing of conduction and a
refractory period prolongation due to post-repolarization refractori-
ness.11 This study shows an use-dependent effect on atrial contractility
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and a decrease in excitability described by increased pacing thresh-
olds and slowing of conduction. The use-dependent effect of vernaka-
lant19–21 on the sodium current may explain the a negative inotropic
effect at faster pacing rates. These haemodynamic and electrophysio-
logic observations in vivo, and ex vivo measurements,19 underscores the
potent and dominant class I effects of vernakalant. This inhibition of so-
dium current presumably will affect NCX function. Specifically, the
reduced voltage dependent sodium current will lead to a decreased
cytosolic sodium concentration, lowering the driving force for
Ca2þ influx through the NCX. Thereby limiting the potential contribu-
tion of the NCX reverse mode on atrial contractility.
Limitations
This animal model requires chronic implantation of electrodes and
crystals. It is likely that this has caused a local inflammation and in turn
affected local electrophysiological and contractile properties. In con-
trol conditions and after the infusion of AV0118 significant atrial
work could clearly be measured but this does not exclude a negative
effect on atrial contractility of the model itself.
Second, in patients with longstanding persistent AF, LA contractil-
ity is affected to a greater extent than the right atrium.22 Our study
only evaluated RA work loops because of the risk of clot formation
caused by chronic implantation of a pressure catheter in the left
atrium. We assume that RA work is in agreement with LA work,
comparable to the lack of effect on FS in both atria. Furthermore, dif-
ferential effects action potential morphology are not expected as we
did not detect differences in effect of vernakalant on ERP or conduc-
tion velocity between both atria a previous study.11
Conclusions
Vernakalant does not affect atrial contractility, arguably because it
does not affect early atrial repolarization. Most likely vernakalant
does not significantly inhibit IKur at clinical relevant plasma levels. Our
data confirm recent observations that vernakalant mainly acts by its
effects on the sodium current.
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